Last 47 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
AbbVie Inc.'s quarterly P/E stands at 56.0x. EV/EBITDA has compressed 90.2% YoY to 15.0x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 91.41 | 56.00 | 582.93 | 87.56 | 72.75 | — | 56.10 | 55.69 | 59.12 | 84.22 | 37.27 | 29.55 | 306.48 |
| — | — | +939.0% | +57.2% | +23.0% | — | +50.5% | +88.5% | -80.7% | +189.8% | +146.6% | -60.6% | +1813.3% | |
| P/S Ratio | 6.26 | 6.10 | 6.50 | 5.33 | 6.96 | 5.22 | 6.05 | 5.25 | 6.56 | 4.80 | 4.74 | 4.30 | 5.79 |
| — | +16.9% | +7.5% | +1.5% | +6.1% | +8.6% | +27.7% | +22.1% | +13.3% | +1.0% | +17.8% | -7.7% | +8.7% | |
| P/B Ratio | — | — | — | — | 253.95 | 93.66 | 57.64 | 44.53 | 40.12 | 26.41 | 21.76 | 18.50 | 21.28 |
| — | — | — | — | +532.9% | +254.6% | +164.8% | +140.7% | +88.6% | +58.9% | +46.3% | -0.1% | +20.4% | |
| P/FCF | 21.51 | 20.73 | 13.63 | 16.84 | 66.30 | 11.66 | 16.83 | 37.41 | 20.98 | 15.09 | 8.97 | 9.71 | 17.61 |
| — | +77.8% | -19.0% | -55.0% | +216.0% | -22.8% | +87.6% | +285.1% | +19.1% | +51.6% | +11.8% | -30.6% | +16.0% | |
| EV / EBITDA | 15.83 | 15.04 | 29.83 | 14.15 | 18.88 | 154.16 | 17.50 | 14.74 | 19.44 | 15.27 | 17.24 | 10.74 | 17.28 |
| — | -90.2% | +70.5% | -4.0% | -2.8% | +909.7% | +1.5% | +37.3% | +12.5% | +36.6% | +58.5% | -31.7% | +31.6% | |
| EV / EBIT | 22.25 | 34.67 | 81.45 | 42.82 | 46.17 | — | 36.89 | 31.45 | 39.21 | 45.31 | 31.05 | 23.00 | 82.30 |
| — | — | +120.8% | +36.2% | +17.7% | — | +18.8% | +36.7% | -52.4% | +87.0% | +108.0% | -52.5% | +407.0% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
AbbVie Inc.'s operating margin was 35.0% in Q4 2025, up 22.9 pp QoQ and up 44.8 pp YoY. The trailing four-quarter average of 26.7% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.2% | 72.6% | 66.4% | 71.8% | 70.0% | 70.9% | 70.9% | 70.9% | 66.7% | 60.1% | 53.4% | 69.4% | 67.4% |
| — | +2.4% | -6.3% | +1.2% | +4.9% | +17.9% | +32.6% | +2.2% | -1.0% | -17.0% | -19.2% | -2.8% | -3.8% | |
| Operating Margin | 32.8% | 35.0% | 12.1% | 31.7% | 28.0% | -9.9% | 26.5% | 27.6% | 22.7% | 22.3% | 16.4% | 32.5% | 22.6% |
| — | +454.3% | -54.4% | +14.8% | +23.1% | -144.2% | +61.8% | -15.1% | +0.4% | -38.6% | -47.3% | +44.1% | -35.0% | |
| Net Margin | 6.9% | 10.9% | 1.2% | 6.1% | 9.6% | -0.1% | 10.8% | 9.5% | 11.1% | 5.7% | 12.8% | 14.6% | 2.0% |
| — | +7600.3% | -89.1% | -35.8% | -13.3% | -102.5% | -15.4% | -35.1% | +468.8% | -64.9% | -52.1% | +130.4% | -94.1% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 6214.7% | — | — | 141.7% | 53.3% | -0.5% | 24.2% | 18.4% | 14.8% | 7.3% | 14.2% | 15.4% | 1.6% |
| — | — | — | +668.9% | +259.0% | -106.4% | +70.4% | +19.3% | +850.0% | -50.8% | -44.7% | +159.2% | -94.5% | |
| ROA | 3.1% | 1.4% | 0.1% | 0.7% | 0.9% | -0.0% | 1.1% | 0.9% | 1.0% | 0.6% | 1.3% | 1.5% | 0.2% |
| — | +8681.6% | -87.5% | -27.2% | -1.8% | -102.6% | -16.4% | -37.2% | +452.0% | -65.6% | -52.8% | +132.4% | -94.4% | |
| ROIC | 23.9% | 7.2% | 2.3% | 5.6% | 4.2% | -1.6% | 4.3% | 4.7% | 3.4% | 4.1% | 2.7% | 5.1% | 2.9% |
| — | +537.1% | -46.4% | +20.8% | +23.1% | -140.3% | +56.1% | -7.6% | +17.1% | -27.7% | -39.3% | +66.6% | -30.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
AbbVie Inc.'s Debt/EBITDA ratio is 8.8x, down from 17.3x last quarter — elevated, raising questions about debt serviceability.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 47.80 | 20.17 | 11.71 | 10.36 | 9.20 | 5.78 | 5.01 | 4.73 | 4.67 |
| — | — | — | — | +419.8% | +248.8% | +133.8% | +118.9% | +97.0% | +55.7% | +15.3% | -4.7% | +3.6% | |
| Debt / EBITDA | 2.45 | 8.83 | 17.33 | 10.15 | 12.11 | 110.85 | 12.03 | 11.52 | 15.19 | 11.41 | 13.45 | 9.01 | 12.68 |
| — | -92.0% | +44.1% | -11.9% | -20.3% | +871.9% | -10.6% | +27.9% | +19.7% | +36.1% | +31.6% | -34.0% | +16.9% | |
| Current Ratio | 0.67 | 0.67 | 0.72 | 0.74 | 0.76 | 0.66 | 0.65 | 0.81 | 0.94 | 0.87 | 0.96 | 0.89 | 0.96 |
| — | +1.7% | +12.3% | -8.8% | -18.8% | -24.3% | -32.5% | -9.9% | -2.5% | -9.5% | +2.9% | +6.0% | +17.8% | |
| Quick Ratio | 0.56 | 0.56 | 0.60 | 0.61 | 0.64 | 0.55 | 0.54 | 0.71 | 0.83 | 0.76 | 0.84 | 0.77 | 0.82 |
| — | +0.8% | +10.6% | -13.5% | -23.7% | -27.7% | -35.6% | -8.2% | +1.6% | -9.3% | +1.2% | +3.2% | +16.0% | |
| Interest Coverage | 3.28 | 4.74 | 1.97 | 3.10 | 3.37 | -2.23 | 3.89 | 3.96 | 3.66 | 3.15 | 4.52 | 5.73 | 1.86 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Deep dive into ABBV consensus models and risk factors.
Wall Street verdict, signals, and target summaries.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ABBV stock.
AbbVie Inc.'s current P/E is 91.4x. The average P/E over the last 4 quarters is 199.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
AbbVie Inc.'s current operating margin is 32.8%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking AbbVie Inc.'s business trajectory between earnings reports.